This HTML5 document contains 46 embedded RDF statements represented using HTML+Microdata notation.

The embedded RDF content will be recognized by any processor of HTML5 Microdata.

Namespace Prefixes

PrefixIRI
n2http://linked.opendata.cz/resource/drugbank/drug/
n13http://linked.opendata.cz/resource/drugbank/drug/DB05265/identifier/pubchem-substance/
dctermshttp://purl.org/dc/terms/
n14http://linked.opendata.cz/resource/drugbank/drug/DB05265/identifier/kegg-drug/
n17http://linked.opendata.cz/resource/drugbank/drug/DB05265/identifier/drugbank/
foafhttp://xmlns.com/foaf/0.1/
n12http://bio2rdf.org/drugbank:
n16http://linked.opendata.cz/resource/drugbank/drug/DB05265/identifier/chemspider/
admshttp://www.w3.org/ns/adms#
n9http://wifo5-03.informatik.uni-mannheim.de/drugbank/resource/drugs/
rdfhttp://www.w3.org/1999/02/22-rdf-syntax-ns#
owlhttp://www.w3.org/2002/07/owl#
n3http://linked.opendata.cz/ontology/drugbank/
n11http://linked.opendata.cz/resource/drugbank/drug/DB05265/identifier/pharmgkb/
n4http://linked.opendata.cz/resource/drugbank/property/
xsdhhttp://www.w3.org/2001/XMLSchema#
n6http://www.drugs.com/international/
n15http://linked.opendata.cz/resource/drugbank/drug/DB05265/identifier/pubchem-compound/

Statements

Subject Item
n2:DB05265
rdf:type
n3:Drug
n3:description
Ecabet is a prescription eye drop for the treatment of dry eye syndrome. Ecabet represents a new class of molecules that increases the quantity and quality of mucin produced by conjunctival goblet cells and corneal epithelia. Mucin is a glycoprotein component of tear film that lubricates while retarding moisture loss from tear evaporation. Ecabet is currently marketed in Japan as an oral agent for treatment of gastric ulcers and gastritis.
n3:group
approved investigational
n3:indication
For the treatment of reflux oesophagitis and peptic ulcer disease.
owl:sameAs
n9:DB05265 n12:DB05265
dcterms:title
Ecabet
adms:identifier
n11:PA165958350 n13:99443230 n14:D07885 n15:65781 n16:570992 n17:DB05265
n3:mechanismOfAction
Ecabet reduces the survival of H. pylori in the stomach and inhibits pepsin activity in the gastric juice of experimental animals. Here we have investigated the effects of ecabet on some of the factors involved in the dynamics of the mucosal barrier, i.e. pepsins and mucins. Pepsin, acid and Helicobacter pylori are major factors in the pathophysiology of peptic ulcer disease and reflux oesophagitis. Ecabet also acts as an inhibitor of H. pylori NADPH oxidase as well as urease. Inhibition of these enzymes prevents bacterial adhesion to gastric mucosa.
n3:synonym
Ecabet sodium Ecabet
n3:salt
n3:synthesisReference
Shinji Narisawa, "Aqueous ecabet sodium solution preparation." U.S. Patent US20040259905, issued December 23, 2004.
foaf:page
n6:ecabet-sodium.html
n3:IUPAC-Name
n4:271B3F77-363D-11E5-9242-09173F13E4C5
n3:InChI
n4:271B3F7D-363D-11E5-9242-09173F13E4C5
n3:Molecular-Formula
n4:271B3F7C-363D-11E5-9242-09173F13E4C5
n3:Molecular-Weight
n4:271B3F79-363D-11E5-9242-09173F13E4C5
n3:Monoisotopic-Weight
n4:271B3F7A-363D-11E5-9242-09173F13E4C5
n3:SMILES
n4:271B3F7B-363D-11E5-9242-09173F13E4C5
n3:Water-Solubility
n4:271B3F75-363D-11E5-9242-09173F13E4C5
n3:logP
n4:271B3F76-363D-11E5-9242-09173F13E4C5 n4:271B3F73-363D-11E5-9242-09173F13E4C5
n3:logS
n4:271B3F74-363D-11E5-9242-09173F13E4C5
n3:H-Bond-Acceptor-Count
n4:271B3F83-363D-11E5-9242-09173F13E4C5
n3:H-Bond-Donor-Count
n4:271B3F84-363D-11E5-9242-09173F13E4C5
n3:InChIKey
n4:271B3F7E-363D-11E5-9242-09173F13E4C5
n3:Polar-Surface-Area--PSA-
n4:271B3F7F-363D-11E5-9242-09173F13E4C5
n3:Polarizability
n4:271B3F81-363D-11E5-9242-09173F13E4C5
n3:Refractivity
n4:271B3F80-363D-11E5-9242-09173F13E4C5
n3:Rotatable-Bond-Count
n4:271B3F82-363D-11E5-9242-09173F13E4C5
n3:casRegistryNumber
33159-27-2
n3:Bioavailability
n4:271B3F88-363D-11E5-9242-09173F13E4C5
n3:Ghose-Filter
n4:271B3F8A-363D-11E5-9242-09173F13E4C5
n3:MDDR-Like-Rule
n4:271B3F8B-363D-11E5-9242-09173F13E4C5
n3:Number-of-Rings
n4:271B3F87-363D-11E5-9242-09173F13E4C5
n3:Physiological-Charge
n4:271B3F86-363D-11E5-9242-09173F13E4C5
n3:Rule-of-Five
n4:271B3F89-363D-11E5-9242-09173F13E4C5
n3:Traditional-IUPAC-Name
n4:271B3F78-363D-11E5-9242-09173F13E4C5
n3:pKa--strongest-acidic-
n4:271B3F85-363D-11E5-9242-09173F13E4C5